Takeda Pharmaceutical Company Ltd. / Innovent Biologics, Inc.

Solid Tumors — NSCLC, Colorectal, Gastric, and Pancreatic Cancers

437K US cases/yr · $85.0B US oncology — IO/ADC-relevant solid tumor market (NSCLC/CRC/gastric/pancreatic) 2024 · 1200 Upfront payment incl. $100M equity (USD MM)

Disease Overview

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of US lung cancer cases; SEER analysis (2000-2022) reports age-adjusted incidence of 36.1 per 100,000, translating to roughly 190,000 new US cases annually (of the ~226,650 projected lung and bronchus cases in 2025). Colorectal cancer (CRC) is the third most common cancer in US adults, with SEER projecting approximately 153,000 new cases and 53,000 deaths in 2025; the second-line metastatic CRC setting remains a major area of unmet need despite advances in EGFR/VEGF-targeted and IO therapies. Gastric (stomach) cancer incidence in the US is approximately 27,000 new cases annually with significant mortality in advanced-stage disease; Claudin 18.2-positive tumors represent roughly 30-40% of gastric adenocarcinomas. Pancreatic cancer, with approximately 67,000 new US cases and 52,000 deaths annually in 2025, remains one of the deadliest solid tumors with 5-year survival below 13% and few effective second-line options. IBI363 targets the IO backbone market (PD-1/IL-2 dual mechanism) across NSCLC/CRC; IBI343 targets the Claudin 18.2 ADC space in gastric/pancreatic cancer — both spaces where Takeda is rebuilding its oncology pipeline ahead of late-decade patent cliffs.

Competitive Landscape

IBI363 competes in the next-generation IO backbone space against: PD-1/IL-2 bispecifics — Sutimlimab-adjacent Phase 1/2 assets; Merck's MK-6194 (IL-2 variant) and peers. PD-1 monotherapy standards — Keytruda (pembrolizumab, Merck), Opdivo (nivolumab, BMS), Tevimbra (tislelizumab, BeiGene). PD-L1/VEGF bispecifics — BNT327/pumitamig (BMS/BioNTech), ivonescimab (Summit/Akeso). IBI343 enters the Claudin 18.2-directed ADC race alongside: Zolbetuximab (Astellas, approved 2024 — monoclonal antibody); AstraZeneca/Daiichi Sankyo's raludotatug deruxtecan peer assets; BioAtla's BA3071; Emergence Therapeutics, Carsgen (CT041 CAR-T for Claudin 18.2). In the broader ADC field, IBI343 benchmarks against Enhertu (trastuzumab deruxtecan) and Trodelvy (sacituzumab govitecan) on payload-conjugate performance. IBI3001 (EGFR/B7H3 bispecific ADC) would enter a crowded bispecific-ADC field that includes Daiichi/Merck's HER3-DXd and emerging dual-payload platforms.